Locked Nucleic Acid Antisense Oligonucleotides Targeting SARS-CoV-2

The inventors have designed and tested Locked Nucleic Acid (LNA) Antisense Oligonucleotides (ASOs) targeting the SARS-CoV-2 Spike RNA and 5′ leader of ORF1ab RNA and identified several hits that exhibit excellent on-target efficacy at 50-100 nM in decreasing viral RNA load (Spike and N RNAs) 48 hours post-infection in human Huh-7 cells, with no apparent toxicity. These LNA ASOs will serve as leads for testing of therapeutic targeting of SARS-CoV-2 in animal models, before possible assessment in human trials. Terri Sale terri.sale@berkeley.edu 510-643-4219

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More